Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2012 Jun 19;15(4):10.1038/pcan.2012.21. doi: 10.1038/pcan.2012.21

Fig. 2.

Fig. 2

Nomogram evaluating 10-year competing risks of death in patients with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy, with or without neoadjuvant/adjuvant ADT. Total point values are independently calculated for each cause of death and then applied to the corresponding probability scale at the bottom of the figure. For example, a 70 year old Caucasian male with 3 comorbidities, a PSA of 5 ng/mL, and cT1c Gleason 7 prostate cancer who plans to undergo RP has a 10-year predicted PCSM of 4% but a 34% risk of death from other causes. On the other hand, a 65 year old Caucasian male without comorbidities, with a PSA of 15 ng/mL and cT2b Gleason 8 prostate cancer, who plans to undergo RT with neoadjuvant/adjuvant ADT has a 15% 10-year PCSM and 22% risk of non-prostate cancer death.